Past, present, and future perspectives on aztreonam and avibactam
Author:
- 4 March 2025
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 23 (5) , 277-290
Abstract
Aztreonam is a monobactam antibiotic approved in 1986 to treat infections caused by aerobic Gram-negative bacteria, but, together with cephalosporins, lost clinical utility due to emergence of extended-spectrum β-lactamases (ESBLs) and novel (serine) carbapenemases. Avibactam was the first in a novel non-β-lactam β-lactamase inhibitor class to inhibit these enzymes effectively. It has been approved in combination with ceftazidime to treat Gram-negative infections caused by bacteria that produce AmpC, ESBLs and serine carbapenemases, and with aztreonam to treat patients infected with metallo-β-lactamase-producing enteric bacteria. Combinations of avibactam with ceftazidime and/or aztreonam have been used successfully to treat enteric pathogens producing multiple classes of β-lactamases. Development of aztreonam, avibactam and avibactam combinations are placed into historical perspective, based on both preclinical and clinical data. A search of MEDLINE/Ovid was used to identify relevant literature. Avibactam combined with ceftazidime and aztreonam in either dual or triple combinations provides the opportunity to treat previously untreatable Gram-negative infections that produce multiple β-lactamases. Aztreonam combinations should be particularly attractive, due to stability to metallo-β-lactamase hydrolysis and its safety advantage in treating penicillin-allergic patients. Other inhibitor combinations in development may challenge these combinations.Keywords
This publication has 115 references indexed in Scilit:
- Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogensPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024
- The Safety of Aztreonam Versus Ceftazidime in Patients Labeled With Penicillin Allergy: A Cohort StudyClinical Therapeutics, 2024
- Outcomes of 23 patients diagnosed with New Delhi metallo-beta-lactamase (NDM)-producing Klebsiella pneumoniae infection treated with ceftazidime/avibactam and aztreonam at a single center in PolandEuropean Journal of Clinical Microbiology & Infectious Diseases, 2024
- In vitro activity of aztreonam–avibactam against Enterobacterales isolates collected in Latin America, Africa/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019–2021European Journal of Clinical Microbiology & Infectious Diseases, 2023
- Cefiderocol resistance genomics in sequential chronic Pseudomonas aeruginosa isolates from cystic fibrosis patientsClinical Microbiology and Infection, 2022
- Antimicrobial activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa and Enterobacterales collected in Croatia, Czech Republic, Hungary, Poland, Latvia and Lithuania: ATLAS Surveillance Program, 2019European Journal of Clinical Microbiology & Infectious Diseases, 2022
- Diversity of extended-spectrum and plasmid-mediated AmpC β-lactamases in Enterobacteriaceae isolates from portuguese health care facilitiesJournal of Microbiology, 2014
- Continuous fluorescence anisotropy-based assay of BOCILLIN FL penicillin reaction with penicillin binding protein 3Analytical Biochemistry, 2013
- Immunogenicity and cross-allergenicity of aztreonamThe American Journal of Medicine, 1990
- Monocyclic β‐lactam antibioticsMedicinal Research Reviews, 1984